Showing results (321-330 of 331) with videos related to

Sort By:
Pageof 34
Diabetes & Metabolism|January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyAvraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
Endocrinology and Metabolism (Seoul, Korea)|March 27, 2019
Medical Treatment with Somatostatin Analogues in Acromegaly: Position StatementSang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, et al.
European Journal of Nutrition|June 10, 2022
Recommendation on an updated standardization of serum magnesium reference rangesAndrea Rosanoff, Christina West, Ronald J Elin, et al.
The Lancet. Diabetes & Endocrinology|November 9, 2025
Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based studyJoanna Y Gong, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|March 12, 2026
Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based studyDianna J Magliano, Jedidiah I Morton, Lei Chen, et al.
Diabetes & Metabolism Journal|October 4, 2023
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes AssociationJong Han Choi, Kyung Ae Lee, Joon Ho Moon, et al.
The Lancet. Diabetes & Endocrinology|January 13, 2022
Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate dataDianna J Magliano, Lei Chen, Bendix Carstensen, et al.
Diabetes & Metabolism Journal|August 6, 2021
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes AssociationKyu Yeon Hur, Min Kyong Moon, Jong Suk Park, et al.
Diabetes & Metabolism Journal|May 19, 2024
Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled TrialJie-Eun Lee, Seung Hee Yu, Sung Rae Kim, et al.
The Lancet. Diabetes & Endocrinology|October 2, 2022
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based studyDunya Tomic, Jedidiah I Morton, Lei Chen, et al.
Pageof 34